Enzon Pharmaceuticals (ENZN): Price and Financial Metrics

Enzon Pharmaceuticals (ENZN): $0.08

0.01 (+7.73%)

POWR Rating

Component Grades

Momentum

NR

Stability

NR

Sentiment

Quality

NR

Add ENZN to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#NR of 481

in industry

ENZN Price/Volume Stats

Current price $0.08 52-week high $0.23
Prev. close $0.07 52-week low $0.06
Day low $0.08 Volume 100
Day high $0.08 Avg. volume 19,281
50-day MA $0.08 Dividend yield N/A
200-day MA $0.13 Market Cap 5.79M

ENZN Stock Price Chart Interactive Chart >


Enzon Pharmaceuticals (ENZN) Company Bio


Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron and Sylatron. The company was founded in 1981 and is headquartered in Cranford, New Jersey.


ENZN Latest News Stream


Event/Time News Detail
Loading, please wait...

ENZN Latest Social Stream


Loading social stream, please wait...

View Full ENZN Social Stream

Latest ENZN News From Around the Web

Below are the latest news stories about ENZON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ENZN as an investment opportunity.

7 Undervalued Biotech Stocks to Buy Before They Boom

Speculative investors should consider building a position in these undervalued biotech stocks before the market rebounds.

Josh Enomoto on InvestorPlace | November 30, 2022

Read More 'ENZN' Stories Here

ENZN Price Returns

1-mo 11.11%
3-mo -5.88%
6-mo -38.74%
1-year -60.98%
3-year -85.72%
5-year 63.27%
YTD -14.53%
2023 -62.06%
2022 -27.97%
2021 37.88%
2020 20.58%
2019 284.33%

Continue Researching ENZN

Here are a few links from around the web to help you further your research on Enzon Pharmaceuticals Inc's stock as an investment opportunity:

Enzon Pharmaceuticals Inc (ENZN) Stock Price | Nasdaq
Enzon Pharmaceuticals Inc (ENZN) Stock Quote, History and News - Yahoo Finance
Enzon Pharmaceuticals Inc (ENZN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!